Screener
Immunome IMNM Operating Lease ROU Assets
Operating Lease ROU Assets at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The source filing: Immunome’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Prepaid expenses and other current assets | 11,616 | 7,295 |
| Total current assets | 594,309 | 660,777 |
| Property and equipment, net | 17,081 | 14,636 |
| Operating right-of-use assets | 2,828 | 2,978 |
| Restricted cash | 210 | 210 |
| Other long-term assets | 5,364 | 4,587 |
| Total assets | $619,792 | $683,188 |
| Liabilities and stockholders’ equity |
Item 1. Financial Statements.
FAQ
- What is Immunome's operating lease ROU assets?
- Immunome (IMNM) reported operating lease ROU assets of $2.83M in Q1 2026.
- How has Immunome's operating lease ROU assets changed year-over-year?
- Immunome's operating lease ROU assets decreased by 32.1% year-over-year, from $4.16M to $2.83M.
- What is the long-term trend for Immunome's operating lease ROU assets?
- Over 4 years (2021 to 2025), Immunome's operating lease ROU assets has grown at a 56.2% compound annual growth rate (CAGR), from $500K to $2.98M.
- What does operating lease ROU assets mean?
- Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.
Ask your AI about Immunome's operating lease rou assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude